SEPN Septerna, Inc.

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

Septerna, Inc. (SEPN) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Septerna (SEPN) disclosed material information via Reg FD, with substantive content in Exhibits 99.1 and 99.2
• "Furnished not filed" status limits legal liability under Exchange Act Section 18 — standard for investor presentations and operational updates

+1 more insights

Item 8.01 · Other Events

• SEP-631 Phase 1 cleared with adverse event profile comparable to placebo — no severe/serious adverse events across all doses
• Once-daily oral dosing supported by ~24-hour half-life and no food-effect restrictions — strong convenience profile for chronic disease use

+3 more insights

Other Septerna, Inc. 8-K Filings

8-K Mar 9, 2026

Get deeper insights on Septerna, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.